North America Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (

North America Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)   

The intravenous immunoglobulin market in North America is expected to grow from US$ 4,653.00 million in 2022 to US$ 7,272.33 by 2028. It is estimated to grow at a CAGR of 7.7% from 2022 to 2028.

Increasing Geriatric Population

As per the 2020 PROFILE OF OLDER AMERICANS report, in 2019, in the US, the population aged 65 and above was 54.1 million—30 million women and 24.1 million men. In 2019, 16% of the total population was aged 65 and above, which is expected to increase to 21.6% by 2040. Since 2009, the geriatric population in the US has increased by 14.4 million (or 36%). Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the increase in the geriatric population across the region is bolstering the growth of the intravenous immunoglobulin market.

Market Overview

The North America intravenous immunoglobulin market has been segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021. Rising number of immunodeficiencies and autoimmune diseases, growing research & development activities on IVIg, and increasing demand for advanced therapies to treat diseases are among the prominent factors propelling the market growth in this region. The US accounts for a significant share of the intravenous immunoglobulin market in North America. The rising number of immunodeficiencies and autoimmune diseases in the US is likely to increase the demand for intravenous immunoglobulin. As per the National Institutes of Health, ~23.5 million Americans (over 7% of the population) suffer from an autoimmune disease, and the number is rising.

North America Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

North America Intravenous Immunoglobulin Market Segmentation

The North America intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

Based on application, the North America intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022. Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022. Based on end user, the North America intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022. Based on country, the market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa antimicrobial coatings for medical devices market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa antimicrobial coatings for medical devices market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the antimicrobial coatings for medical devices market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution